135 related articles for article (PubMed ID: 30572204)
1. Development and validation of an UPLC-MS/MS bioanalytical method for simultaneous quantification of the antiretroviral drugs dolutegravir, elvitegravir, raltegravir, nevirapine and etravirine in human plasma.
Bollen PDJ; de Graaff-Teulen MJA; Schalkwijk S; van Erp NP; Burger DM
J Chromatogr B Analyt Technol Biomed Life Sci; 2019 Jan; 1105():76-84. PubMed ID: 30572204
[TBL] [Abstract][Full Text] [Related]
2. UPLC-MS/MS method for the simultaneous quantification of three new antiretroviral drugs, dolutegravir, elvitegravir and rilpivirine, and other thirteen antiretroviral agents plus cobicistat and ritonavir boosters in human plasma.
Simiele M; Ariaudo A; De Nicolò A; Favata F; Ferrante M; Carcieri C; Bonora S; Di Perri G; De Avolio A
J Pharm Biomed Anal; 2017 May; 138():223-230. PubMed ID: 28219799
[TBL] [Abstract][Full Text] [Related]
3. High-performance liquid chromatography-tandem mass spectrometry for simultaneous determination of raltegravir, dolutegravir and elvitegravir concentrations in human plasma and cerebrospinal fluid samples.
Tsuchiya K; Ohuchi M; Yamane N; Aikawa H; Gatanaga H; Oka S; Hamada A
Biomed Chromatogr; 2018 Feb; 32(2):. PubMed ID: 28762239
[TBL] [Abstract][Full Text] [Related]
4. Simultaneous quantification of tenofovir, emtricitabine, rilpivirine, elvitegravir and dolutegravir in mouse biological matrices by LC-MS/MS and its application to a pharmacokinetic study.
Prathipati PK; Mandal S; Destache CJ
J Pharm Biomed Anal; 2016 Sep; 129():473-481. PubMed ID: 27497648
[TBL] [Abstract][Full Text] [Related]
5. Validation of a fast method for quantitative analysis of elvitegravir, raltegravir, maraviroc, etravirine, tenofovir, boceprevir and 10 other antiretroviral agents in human plasma samples with a new UPLC-MS/MS technology.
Djerada Z; Feliu C; Tournois C; Vautier D; Binet L; Robinet A; Marty H; Gozalo C; Lamiable D; Millart H
J Pharm Biomed Anal; 2013 Dec; 86():100-11. PubMed ID: 23995753
[TBL] [Abstract][Full Text] [Related]
6. The development and application of a novel LC-MS/MS method for the measurement of Dolutegravir, Elvitegravir and Cobicistat in human plasma.
Penchala SD; Fawcett S; Else L; Egan D; Amara A; Elliot E; Challenger E; Back D; Boffito M; Khoo S
J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Aug; 1027():174-80. PubMed ID: 27290668
[TBL] [Abstract][Full Text] [Related]
7. A sensitive HPLC-MS/MS method for the determination of dolutegravir in human plasma.
Bennetto-Hood C; Tabolt G; Savina P; Acosta EP
J Chromatogr B Analyt Technol Biomed Life Sci; 2014 Jan; 945-946():225-32. PubMed ID: 24361860
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic profile of raltegravir, elvitegravir and dolutegravir in plasma and mucosal secretions in rhesus macaques.
Massud I; Martin A; Dinh C; Mitchell J; Jenkins L; Heneine W; Pau CP; García-Lerma JG
J Antimicrob Chemother; 2015 May; 70(5):1473-81. PubMed ID: 25630643
[TBL] [Abstract][Full Text] [Related]
9. Development and validation of a multiplex UHPLC-MS/MS assay with stable isotopic internal standards for the monitoring of the plasma concentrations of the antiretroviral drugs bictegravir, cabotegravir, doravirine, and rilpivirine in people living with HIV.
Courlet P; Alves Saldanha S; Cavassini M; Marzolini C; Choong E; Csajka C; Günthard HF; André P; Buclin T; Desfontaine V; Decosterd LA
J Mass Spectrom; 2020 Jun; 55(6):e4506. PubMed ID: 32160389
[TBL] [Abstract][Full Text] [Related]
10. A validated assay by liquid chromatography-tandem mass spectrometry for the simultaneous quantification of elvitegravir and rilpivirine in HIV positive patients.
Aouri M; Calmy A; Hirschel B; Telenti A; Buclin T; Cavassini M; Rauch A; Decosterd LA
J Mass Spectrom; 2013 May; 48(5):616-25. PubMed ID: 23674286
[TBL] [Abstract][Full Text] [Related]
11. Validation of an electrospray ionization LC-MS/MS method for quantitative analysis of raltegravir, etravirine, and 9 other antiretroviral agents in human plasma samples.
Quaranta S; Woloch C; Paccou A; Giocanti M; Solas C; Lacarelle B
Ther Drug Monit; 2009 Dec; 31(6):695-702. PubMed ID: 19865000
[TBL] [Abstract][Full Text] [Related]
12. Development of a simple and rapid method to determine the unbound fraction of dolutegravir, raltegravir and darunavir in human plasma using ultrafiltration and LC-MS/MS.
Zheng Y; Lui G; Boujaafar S; Aboura R; Bouazza N; Foissac F; Treluyer JM; Benaboud S; Hirt D; Gana I
J Pharm Biomed Anal; 2021 Mar; 196():113923. PubMed ID: 33571728
[TBL] [Abstract][Full Text] [Related]
13. Development and validation of an ultra-high performance liquid chromatography-tandem mass spectrometry method to quantify antiretroviral drug concentrations in human plasma for therapeutic monitoring.
West RE; Oberly PJ; Riddler SA; Nolin TD; Devanathan AS
J Pharm Biomed Anal; 2024 Mar; 240():115932. PubMed ID: 38198884
[TBL] [Abstract][Full Text] [Related]
14. UPLC-MS/MS method for the simultaneous quantification of bictegravir and 13 others antiretroviral drugs plus cobicistat and ritonavir boosters in human plasma.
Gouget H; Noé G; Barrail-Tran A; Furlan V
J Pharm Biomed Anal; 2020 Mar; 181():113057. PubMed ID: 31962247
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and Placental Transfer of Elvitegravir, Dolutegravir, and Other Antiretrovirals during Pregnancy.
Rimawi BH; Johnson E; Rajakumar A; Tao S; Jiang Y; Gillespie S; Schinazi RF; Mirochnick M; Badell ML; Chakraborty R
Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28348149
[TBL] [Abstract][Full Text] [Related]
16. An HPLC-PDA method for the simultaneous quantification of the HIV integrase inhibitor raltegravir, the new nonnucleoside reverse transcriptase inhibitor etravirine, and 11 other antiretroviral agents in the plasma of HIV-infected patients.
D'Avolio A; Baietto L; Siccardi M; Sciandra M; Simiele M; Oddone V; Bonora S; Di Perri G
Ther Drug Monit; 2008 Dec; 30(6):662-9. PubMed ID: 18824956
[TBL] [Abstract][Full Text] [Related]
17. HPLC-MS/MS method for the simultaneous quantification of dolutegravir, elvitegravir, rilpivirine, darunavir, ritonavir, raltegravir and raltegravir-β-d-glucuronide in human plasma.
Zheng Y; Aboura R; Boujaafar S; Lui G; Hirt D; Bouazza N; Foissac F; Treluyer JM; Benaboud S; Gana I
J Pharm Biomed Anal; 2020 Apr; 182():113119. PubMed ID: 32004775
[TBL] [Abstract][Full Text] [Related]
18. A Validated Method for Quantification of Dolutegravir Using Ultra Performance Liquid Chromatography Coupled With UV Detection.
Wang X; Penchala SD; Amara A; Else L; McClure M; Boffito M
Ther Drug Monit; 2016 Jun; 38(3):327-31. PubMed ID: 26859200
[TBL] [Abstract][Full Text] [Related]
19. Development and validation of a liquid chromatographic-tandem mass spectrometric method for the multiplexed quantification of etravirine, maraviroc, raltegravir, and rilpivirine in human plasma and tissue.
Parsons TL; Marzinke MA
J Pharm Biomed Anal; 2016 Nov; 131():333-344. PubMed ID: 27632783
[TBL] [Abstract][Full Text] [Related]
20. Dolutegravir and elvitegravir plasma concentrations following cessation of drug intake.
Elliot E; Amara A; Jackson A; Moyle G; Else L; Khoo S; Back D; Owen A; Boffito M
J Antimicrob Chemother; 2016 Apr; 71(4):1031-6. PubMed ID: 26679246
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
